Takeda 204


To assess the safety and effectiveness of treatment with daily oral administration of dexlansoprazole delayed release capsules (15,30, and 60 mg) in pediatric subjects aged 1 to 11 years with symptomatic nonerosive GERD.


Pediatric Subjects Aged 1 to 11 Years With Symptomatic Nonerosive Gastroesophageal Reflux Disease


Subjects 1-11 years old with symptomatic Nonerosive GERD will be enrolled in the study.  Subjects will undergo an Endoscopy and will have lab tests at most visits

Interested in more information? Contact Us:

Sunny Hussain, M.D., Principal Investigator
(318) 212-8130

IRB: Willis-Knighton
IRB Number:
Trial Type: Drug
Sponsor: Takeda